{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=41",
    "query": {
      "condition": "Metastatic Solid Cancer",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 1764,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Cancer&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T19:49:02.786Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05118789",
      "title": "A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Zidesamtinib (NVL-520)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvalent Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 359,
      "start_date": "2022-01-04",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 20,
      "location_summary": "Orange, California • Palo Alto, California • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05118789"
    },
    {
      "nct_id": "NCT03875313",
      "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "TNBC - Triple-Negative Breast Cancer",
        "Colorectal Cancer",
        "CRC",
        "RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2019-05-20",
      "completion_date": "2020-07-29",
      "has_results": true,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03875313"
    },
    {
      "nct_id": "NCT06108050",
      "title": "JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "JZP898",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2023-11-07",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 10,
      "location_summary": "Encinitas, California • Fresno, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06108050"
    },
    {
      "nct_id": "NCT04693468",
      "title": "Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib Isethionate",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2020-12-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04693468"
    },
    {
      "nct_id": "NCT04797468",
      "title": "A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "HLX23",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-07-18",
      "completion_date": "2023-01-13",
      "has_results": false,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Orange, California • Orange City, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04797468"
    },
    {
      "nct_id": "NCT05856981",
      "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Metastatic Solid Tumor",
        "Refractory Cancer",
        "CRC, Colorectal Cancer",
        "RCC, Clear Cell Adenocarcinoma",
        "NSCLC (Advanced Non-small Cell Lung Cancer)",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "ADU-1805",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sairopa B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2023-04-03",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 8,
      "location_summary": "Detroit, Michigan • St Louis, Missouri • Charlotte, North Carolina + 5 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05856981"
    },
    {
      "nct_id": "NCT04866134",
      "title": "A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ERAS-007",
          "type": "DRUG"
        },
        {
          "name": "ERAS-601",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 85,
      "start_date": "2021-05-07",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04866134"
    },
    {
      "nct_id": "NCT04900818",
      "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Gastric Cancer",
        "Gastroesophageal Junction Carcinoma",
        "Esophageal Adenocarcinoma",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Biliary Tract Cancer (BTC)"
      ],
      "interventions": [
        {
          "name": "TJ033721 (givastomig)",
          "type": "DRUG"
        },
        {
          "name": "TJ033721 (givastomig) , nivolumab, chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "TJ033721 (givastomig), chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "TJ033721 (givastomig), durvalumab, chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "I-Mab Biopharma US Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2021-06-29",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 11,
      "location_summary": "Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Layfayette",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04900818"
    },
    {
      "nct_id": "NCT07762703",
      "title": "Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple-Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "BreakVax",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Standard-of-care chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Losartan and aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BreakBio Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 10,
      "start_date": "2026-09",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07762703"
    },
    {
      "nct_id": "NCT00741403",
      "title": "A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Lymphoma",
        "Solid Tumors",
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "CPI-613",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornerstone Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2008-08",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-29",
      "last_synced_at": "2026-11-15T19:49:02.786Z",
      "location_count": 3,
      "location_summary": "Peoria, Arizona • The Bronx, New York • Dallas, Texas",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00741403"
    }
  ]
}